Pelvic inflammatory disease affects between 10% and 20% women suffering from gonococcal infection. Also there are chances that 20% to 40% of women with cervical chlamydial infection may eventually develop pelvic inflammatory disease.

The rising incidence of the diseases has left governments with fewer options but to invest in better diagnosis methods. Favorable regulations are thus implemented to encourage investment toward research and development of Pelvic Inflammatory Diseases, enabling growth in the global pelvic inflammatory diseases market. As per the US Department of Health and Human Services, nearly 36.7 million people around the world were living with HIV/AIDS till the end of 2015. The condition may accelerate the pelvic inflammatory disease. Therefore the rising incidence of HIV/AIDS, coupled with the increasing research and development and the growing awareness among people has fared well for the global pelvic inflammatory disease market. On the downside, side-effects of the treatment procedures and a competitive environment may hinder the market’s trajectory to an extent.

The global pelvic inflammatory disease market can be segmented based on the type of products, disease type, distribution channel, dosage form, and regions. Based on disease type, the global pelvic inflammatory disease market can be segmented as chronic pelvic inflammatory disease, sexually transmitted pelvic inflammatory disease, subacute pelvic inflammatory disease, and acute pelvic inflammatory disease. Based on product, the market can be categorized into Aminoglycosides, Macrolides, Cephalosporins, Tetracyclines, and others. In terms of dosage form, intramascular, oral, and parenteral constitute the key market segments. The report provides insights into the various factors influencing the market’s growth across the aforementioned segments.

Regionally, North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa are identified as the key market segments. According to the report, North America exhibits highly lucrative opportunities for the pelvic inflammatory disease market. However, considering the population growth in Asia Pacific and the rising incidence of the diseases witnessed in the region, its CAGR is expected to be faster than North America.

The report also profiles some of the leading enterprises operating in the global pelvic inflammatory disease market. Some of these companies are Sanofi S.A., F. Hoffmann-La Roche Ltd, Teligent Inc., Pfizer Inc., Hospira Inc., and GlaxoSmithKline LLC. The profiles of some of the most prominent companies such as these are included in the report and they are studied on the basis of their financial overview, product portfolio, and recent strategies. Furthermore, the strengths and weaknesses of the companies profiled are identified. Besides this the report also highlights the opportunities and threats that these companies may face over the course of the forecast period.

Download a PDF Brochure of Report –